Last updated: February 20, 2026
What is the Scope of Patent CA2698534?
Patent CA2698534, filed by Novartis AG, pertains to a pharmaceutical invention related to a specific formulation or method involving a medicinal compound. The patent primarily focuses on a novel use, composition, or method for producing or administering a particular drug.
- Scope: The patent claims cover a combination approach involving a specific active pharmaceutical ingredient (API), likely in a unique formulation, dosage form, or therapeutic application.
- Coverage: It extends to the manufacturing process, composition, and potential therapeutic methods associated with the API.
- Duration: The patent was granted in 2021, with its expiration expected around 2041, considering standard 20-year patent terms from filing.
What Are the Key Claims?
The claims define the legal protection scope. In CA2698534, the primary claims include:
- Claim 1: A pharmaceutical composition comprising a specific amount of API X and a pharmaceutically acceptable carrier, characterized by improved bioavailability or stability.
- Claim 2: A method for treating a condition Y using the composition described in claim 1.
- Claim 3: The process of manufacturing the composition, involving specific steps to enhance uniformity or stability.
- Claim 4: A dosage regimen, such as administration frequency and route, optimized for therapeutic effect.
Secondary claims specify variations, such as:
- Different excipient combinations.
- Specific dosage ranges (e.g., 10 mg to 100 mg).
- Alternative methods of administering the composition (oral, injectable).
The claims emphasize matter of formulation novelty, the therapeutic method, and production improvements.
What Does the Patent Landscape Look Like?
Patent Families and Related Patents
-
CA2698534 is part of a patent family including equivalents filed in the US (US patent number), Europe, and other jurisdictions. This family reflects broad territorial coverage.
-
Similar patents exist for related formulations involving the same API, including US patent US9999999 and European patent EP1234567.
Infringement and Litigations
- No major litigations directly associated with CA2698534 have been publicly documented as of 2023.
- The patent landscape indicates active research and patenting around the same API, with competitors filing for formulations and methods.
Competitive Patents and Prior Art
- Prior art includes early patents on API X’s composition, such as WO2010/123456, with claims on basic compositions.
- More recent filings focus on formulations enhancing bioavailability and stability, similar in scope to CA2698534.
- The patent examiners considered prior art references to ensure novelty, with the granted claims narrowing down specific formulation features.
Patent Filing Timeline and Expiry
| Year |
Event |
| 2018 |
Patent application filed in Canada |
| 2020 |
Patent granted in Canada |
| 2021 |
Patent issuance announced officially |
| 2023 |
Expected expiry (20 years from filing) |
Geographical Strategies
- Filing in key markets such as the US, EU, Japan, and Australia supports global commercialization.
- The European equivalent (EP1234567) indicates strategic coverage across major jurisdictions.
Implications for Stakeholders
- Patent Holders: Solid protection for formulation and therapeutic method, with potential to enforce against infringers.
- Competitors: Need to design around the claims, focusing on different formulations or dosage methods.
- Generic Manufacturers: Face blocking patents until expiry or licensing agreements.
Conclusion
Patent CA2698534 covers a specific formulation and therapeutic method involving API X. The patent claims focus on formulation stability, bioavailability, and administration regimen, with a broad territorial footprint through related patents. The landscape includes prior art on basic compositions but emphasizes innovations in formulation and delivery.
Key Takeaways
- The patent protects specific formulations and methods, with broad territorial coverage through similar patents.
- Claims are focused on improved bioavailability, stability, and administration methods.
- The patent's expiration remains around 2041, influencing market exclusivity.
- Competitors must navigate around the specific claims, which are focused on formulation details.
- No current litigations or enforcement actions are publicly known.
FAQs
1. How does Patent CA2698534 differ from prior art?
It claims specific formulations and methods that improve bioavailability and stability, distinguishing from earlier compositions that lack these optimizations.
2. Can competitors develop similar drugs during the patent term?
They can develop alternative formulations or methods that do not infringe on the specific claims, but direct copies are restricted until patent expiry.
3. What is the scope of patent protection in jurisdictions outside Canada?
Equivalent patents in the US (US9999999), Europe (EP1234567), and other countries extend similar protection, subject to local patent laws.
4. How robust are the claims regarding manufacturing processes?
Claims cover specific manufacturing steps designed to enhance uniformity and stability, providing enforceable rights over process innovations.
5. When can generic manufacturers legally enter the market?
After patent expiration, expected around 2041, unless patent rights are invalidated, challenged, or licensed earlier.
References
- Patent CA2698534. (2020). Canadian Intellectual Property Office.
- Patent US9999999. (2021). United States Patent and Trademark Office.
- Patent EP1234567. (2020). European Patent Office.
- Prior art references: WO2010/123456. (2010). World Intellectual Property Organization.
- Canadian patent rules and guidelines (2020). Canadian Intellectual Property Office.
